

-
- detection of Mullerian inhibiting substance. *Am J Anat.*, 156: 265-284.
- **Price JM, Donahoe PK, Ito Y and Hendren III WH (1977):** Programmed cell death in the Mullerian duct induced by Mullerian inhibiting substance. *Am J Anat.*, 149: 353-375.
 - **Puls LE, Hamous J, Morrow MS, Schneyer A, MacLaughlin DT and Castracane VD (1994):** Recurrent ovarian sex cord tumor with annular tubules: tumor marker and chemotherapy experience. *Gynecol Oncol.*, 54: 396-401.
 - **Rajpert-De Meyts E, Jorgensen N, Graem N, Muller J, Cate RL and Skakkebaek NE (1999):** Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. *J. Clin. Endocrinol. Metab.*, 84: 3836-3844.
 - **Rey R, Lordereau-Richard I, Carel JC, Barbet P, Cate RL, Roger M, Chaussain JL & Josso N (1993):** Anti-Müllerian hormone and testosterone serum levels are inversely related during normal and precocious pubertal development. *Journal of Clinical Endocrinology and Metabolism*;77: 1220-1226.
 - **Rey R, Sabourin JC, Venara M, Long WQ, Jaubert F, Zeller WP, Duvillard P, Chemes H and Bidart JM (2000):** Anti-Mullerian hormone is a specific marker of Sertoli- and granulosa-cell origin in gonadal tumors. *Hum Pathol.*, 31: 1202-1208.
 - **Rey RA, Belville C, Nihoul-Fekete C, Michel-Calemard L, Forest MG, Lahlou N, Jaubert F, Mowszowicz I, David M, Saka N, Bouvattier C, Bertrand AM, Lecointre C, Soskin S, Cabrol S, Crosnier H, Leger J, Lortat-Jacob S, Nicolino M, Rabl W, Toledo SP, Bas F, Gompel A, Czernichow P, Chatelain P, Rappaport R,**
-

-
- Morel Y and Josso N (1999):** Evaluation of gonadal function in 107 intersex patients by means of serum anti-Mullerian hormone measurement. *J Clin Endocrinol Metab.*, 84: 627-631.
- **Rey RA, Lhomme C, Marcillac I, Lahlou N, Duvillard P, Josso N and Bidart JM (1996):** Anti-Mullerian hormone as a serum marker of granulosa cell tumors of the ovary: comparative study with serum inhibin and estradiol. *Am J Obstet Gynecol.*, 174: 958-965.
 - **Rittmaster R (1993):** Treating hirsutism. *Endocrinologist* 1993; 3: 211-218.
 - **Roberts LM, Hirokawa Y, Nachtigal MW and Ingraham HA (1999):** Paracrine-mediated apoptosis in reproductive tract development. *Dev Biol.*, 208: 110-122.
 - **Roden DA, Bano G, Bland JM (1998):** Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. *Clin Endocrinol*; 49: 91-99.
 - **Rosner W (2001):** An extraordinarily inaccurate assay for free testosterone is still with us. *J Clin Endocrinol Metab*; 86: 2903.
 - **Saunders JW (1966):** Death in embryonic systems. *Science*, 154: 604-612.
 - **Schofl C, Horn R, Schill T (2005):** Circulating ghrelin levels in patients with polycystic ovary syndrome. *J Clin Endocrinol Metab*; 87: 4607-4610.
 - **Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM F (2002):** Early follicular serum Mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. *Fertil Steril* 77: 468-471.
-

-
- **Seifer DB, MacLaughlin DT, Penzias AS, Behrman HR, Asmundson L, Donahoe PK, Haning RVJ and Flynn SD (1993):** Gonadotropin releasing hormone agonist-induced differences in granulosa cell cycle kinetics are associated with alterations in follicular fluid Mullerian-inhibiting substance and androgen content. *J Clin Endocrinol Metab.*, 76: 711-714.
 - **Sheehan MT (2004):** Polycystic Ovarian Syndrome: Diagnosis and Management *Clinical Medicine & Research* (2): 13-27.
 - **Silfen ME, Manibo AM, McMahon DJ, Levine LS, Murphy AR, Oberfield SE (2001):** Comparison of simple measures of insulin sensitivity in young girls with premature adrenarche: the fasting glucose to insulin ratio may be a simple and useful measure. *J Clin Endocrinol Metab* 2001; 86: 2863-2868.
 - **Solovyeva EV, Hayashi M, Margi K (2000):** Growth differentiation factor-9 stimulates rat theca-interstitial cell androgen biosynthesis. *Biol Reprod*; 63: 1214-1218.
 - **Stein IF, Leventhal ML (2003):** Amenorrhea associated with bilateral polycystic ovaries. *Am J Obstet Gynecol*; 29: 181-191.
 - **Strauss JF III and Dunaif A (1999):** Molecular mysteries of polycystic ovary syndrome. *Mol Endocrinol*; 13: 800-805.
 - **Stubbs SA, Hardy K, Da Silva-Buttkus P, Stark J, Webber LJ, Flanagan AM, Themmen APN, Visser JA, Groome NP & Franks S (2005):** Anti-Müllerian hormone protein expression is reduced during the initial stages of follicle development in human polycystic ovaries. *Journal of Clinical Endocrinology and Metabolism*; 90: 5536-5543.
-

-
-
- **Swain A and Lovell-Badge R (1999):** Mammalian sex determination: a molecular drama. *Genes Dev.*, 13: 755-767.
 - **Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, (2000):** Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. *Arterioscler Thromb Vasc Biol* 20; 20: 2414-2421.
 - **Task Force on the Phenotype of the Polycystic Ovary Syndrome of the Androgen Excess Society (2006):** The Androgen Excess Society evidence-based criteria for defining the polycystic ovary syndrome as a predominantly hyperandrogenic syndrome. *J Clin Endocrinol Metab*; 91: 9237-9245.
 - **Taylor AE, McCourt B, Martin KA (1997):** Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. *J Clin Endocrinol Metab*; 82: 2248-2256.
 - **Teixeira Filho FL, Baracat EC, Lee TH (2002):** Aberrant expression of growth differentiation factor-9 in oocytes of women with polycystic ovary syndrome. *J Clin Endocrinol Metab*; 87: 1337-1344.
 - **Teixeira J and Donahoe PK (1996):** Molecular biology of MIS and its receptors. *J Androl.*, 17: 336-341.
 - **Teixeira J, Maheswaran S and Donahoe PK (2001):** Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. *Endocrine Reviews*, 22: 657-674.
 - **Thomson RL, Buckley JD, Moran LJ, Noakes M, Clifton PM, Norman RJ & Brinkworth GD (2009):** The effect of weight loss on anti-Müllerian hormone levels in overweight and obese women with
-
-

-
- polycystic ovary syndrome and reproductive impairment. *Human Reproduction*; 24: 1976-1981.
- **Tiwary CM (1998):** Premature sexual development in children following the use of estrogen- or placenta-containing hair products. *Clin Pediatr*; 37: 733-740.
 - **Trader BC, Pall M, Azziz R (2006):** Prevalence of Polycystic Ovary Syndrome (PCOS) In a Group of Women Presenting With Oligomenorrhea or Hirsutism: NIH 1990 vs. Rotterdam 2003 Criteria. *The 88th Annual Meeting of the Endocrine Society*. Boston; 26: 24-27.
 - **Trelstad RL, Hayashi A, Hayashi K and Donahoe PK (1982):** The epithelial- mesenchymal interface of the male Mullerian duct: loss of basement membrane integrity and ductal regression. *Dev Biol.*, 92: 27-40.
 - **Trivax B and Azziz R (2007):** Diagnosis of Polycystic Ovary Syndrome. *Clinical Obstetrics and Gynecology*; 50(1): 168-177.
 - **Tsuji M, Shima H, Yonemura CY, Brody J, Donahoe PK and Cunha GR (1992):** Effect of human recombinant Mullerian inhibiting substance on isolated epithelial and mesenchymal cells during Mullerian duct regression in the rat. *Endocrinology*, 131: 1481-1488.
 - **Udoff LC and Adashi EY (1997):** Intraovarian regulation of ovarian androgen secretion in PCOS. In: *Androgen Excess Disorders in Women*. Azziz R, Nestler JE and Dewailly D (eds) LippincottRaven, Philadelphia, USA; 19: 295-301.
 - **Ueno S, Kuroda T, MacLaughlin DT, Ragin RC, Manganaro TF and Donahoe PK (1989a):** Müllerian inhibiting substance in the adult rat ovary during various stages of the estrous cycle. *Endocrinology*, 125: 1060-1066.
-